Detalhe da pesquisa
1.
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Cancer Sci
; 115(4): 1296-1305, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402853
2.
IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.
Cancer Sci
; 112(4): 1534-1544, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462883
3.
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Jpn J Clin Oncol
; 51(8): 1261-1268, 2021 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34037224
4.
Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIß in regulation of the decatenation checkpoint.
Nucleic Acids Res
; 45(10): 5995-6010, 2017 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28472494
5.
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Int J Clin Oncol
; 22(1): 70-78, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27659294
6.
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
Thorac Cancer
; 15(2): 163-171, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38013668
7.
Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study.
Thorac Cancer
; 14(3): 231-236, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36404396
8.
Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Int J Clin Oncol
; 22(1): 79, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27747455
9.
Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
Thorac Cancer
; 13(3): 453-459, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34964270
10.
Tyrosine 656 in topoisomerase IIß is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.
Proteomics
; 11(5): 829-42, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21280220
11.
Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.
Nucleic Acids Res
; 37(2): 382-92, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19043076
12.
Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis?
Acta Med Okayama
; 65(4): 259-63, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21860532
13.
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Cancer Chemother Pharmacol
; 82(6): 1031-1038, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30276451
14.
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
J Thorac Oncol
; 13(2): 273-279, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29313813
15.
Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.
Asian Pac J Cancer Prev
; 8(2): 221-4, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17696735
16.
A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
Lung Cancer
; 112: 188-194, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29191594
17.
Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Anticancer Res
; 26(3A): 1869-76, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16827119
18.
Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.
Mol Cancer Ther
; 4(12): 1880-90, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16373703
19.
Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 17(1): 24-9.e1, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26336854
20.
Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Clin Cancer Res
; 8(1): 287-92, 2002 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11801571